MCID: MNN020
MIFTS: 47

Meningococcal Infection

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Meningococcal Infection

MalaCards integrated aliases for Meningococcal Infection:

Name: Meningococcal Infection 49
Meningococcal Infections 40 69

Classifications:



External Ids:

ICD10 32 A39
UMLS 69 C0025303

Summaries for Meningococcal Infection

MedlinePlus : 40 Meningococci are a type of bacteria that cause serious infections. The most common infection is meningitis, which is an inflammation of the thin tissue that surrounds the brain and spinal cord. Meningococci can also cause other problems, including a serious bloodstream infection called sepsis. Meningococcal infections can spread from person to person. Risk factors include Age - it is more common in infants, teens, and young adults Living in close quarters, such as in college dorms or military settings Certain medical conditions, such as not having a spleen Travel to areas where meningococcal disease is common In its early stages, you may have flu-like symptoms and a stiff neck. But the disease can progress quickly and can be fatal. Early diagnosis and treatment are extremely important. Lab tests on your blood and cerebrospinal fluid can tell if you have it. Treatment is with antibiotics. Since the infection spreads from person to person, family members may also need to be treated. A vaccine can prevent meningococcal infections.

MalaCards based summary : Meningococcal Infection, also known as meningococcal infections, is related to myocardial infarction and waterhouse-friderichsen syndrome, and has symptoms including pruritus and fever. An important gene associated with Meningococcal Infection is C7 (Complement C7), and among its related pathways/superpathways are Aldosterone synthesis and secretion and G-protein signaling G-Protein alpha-i signaling cascades. The drugs Ciprofloxacin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and spinal cord, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Meningococcal Infection

Diseases related to Meningococcal Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Related Disease Score Top Affiliating Genes
1 myocardial infarction 28.2 ADD1 ADRB1 ADRB2 AGT AGTR1
2 waterhouse-friderichsen syndrome 11.5
3 neisseria meningitidis infection 11.4
4 meningitis 11.3
5 properdin deficiency, x-linked 11.3
6 complement factor h deficiency 10.9
7 congenital methemoglobinemia 10.4 G6PD SOD1
8 lymphosarcoma 10.4 G6PD GSR
9 resting heart rate, variation in 10.3 ADRB1 ADRB2
10 methemoglobinemia 10.3 G6PD SOD1
11 ocular hypotension 10.3 ADRB1 ADRB2
12 senile cataract 10.2 G6PD GSR SOD1
13 myocardial stunning 10.2 AGTR1 SOD1
14 pediatric hypertension 10.1 ADD1 AGT
15 posterior urethral valves 10.1 AGT AGTR1
16 meningococcal meningitis 10.1
17 anuria 10.1 AGT AGTR1
18 diastolic heart failure 10.1 AGT AGTR1
19 malignant hypertension 10.1 AGT AGTR1
20 renovascular hypertension 10.1 AGTR1 SOD1
21 fibromuscular dysplasia 10.0 AGT AGTR1
22 retinitis pigmentosa 7 10.0 ROM1 TTR
23 microvascular complications of diabetes 3 10.0 AGT AGTR1
24 disseminated intravascular coagulation 10.0
25 oligohydramnios 10.0 AGT AGTR1
26 aging 9.9
27 complement deficiency 9.9
28 renal tubular dysgenesis 9.9 AGT AGTR1
29 ischemic optic neuropathy 9.9 AGT AGTR1 G6PD
30 orthostatic intolerance 9.9 ADRB1 ADRB2 AGTR1
31 familial hypertension 9.9 AGT AGTR1
32 congestive heart failure 9.9 ADRB1 ADRB2 AGTR1
33 nephrosclerosis 9.9 ADRB1 AGTR1
34 pericarditis 9.9
35 acute mountain sickness 9.9 ADRB2 AGTR1
36 meningococcemia 9.8
37 blood group, i system 9.8
38 mucositis 9.8
39 properdin deficiency 9.8
40 malaria 9.8
41 hepatitis 9.8
42 bacterial meningitis 9.8
43 atrial fibrillation 9.8 ADRB1 AGT AGTR1
44 osteonecrosis 9.6
45 thrombocytopenia 9.6
46 systemic lupus erythematosus 9.6
47 complement component 8 deficiency 9.6
48 pharyngitis 9.6
49 branchiootic syndrome 1 9.6
50 cerebritis 9.6

Graphical network of the top 20 diseases related to Meningococcal Infection:



Diseases related to Meningococcal Infection

Symptoms & Phenotypes for Meningococcal Infection

UMLS symptoms related to Meningococcal Infection:


pruritus, fever

MGI Mouse Phenotypes related to Meningococcal Infection:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ADRB1 ADRB2 AGT AGTR1 G6PD GSR
2 growth/size/body region MP:0005378 9.56 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2
3 homeostasis/metabolism MP:0005376 9.28 SOD1 TTR ADD1 ADRB1 ADRB2 AGT

Drugs & Therapeutics for Meningococcal Infection

Drugs for Meningococcal Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4 3871
3 Complement Factor H Phase 4
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
6 Immunoglobulins Phase 4,Phase 3,Phase 2
7 Antibodies Phase 4,Phase 3,Phase 2
8 Cathartics Phase 4,Phase 3,Phase 2
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Topoisomerase Inhibitors Phase 4
11 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Anti-Bacterial Agents Phase 4,Phase 3
14 Anti-Infective Agents Phase 4,Phase 3
15 Laxatives Phase 4,Phase 3,Phase 2
16 histidine Nutraceutical Phase 4
17
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 5460373 44475014 11953898
18
Iron Approved Phase 3,Phase 2 7439-89-6 23925
19
Acetaminophen Approved Phase 3 103-90-2 1983
20
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
21
Edetic Acid Approved, Vet_approved Phase 3,Phase 2 60-00-4, 62-33-9 6049
22
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
23
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
24 Vitamin B 12 Phase 3,Phase 2
25 Analgesics Phase 3
26 Fibrinolytic Agents Phase 3
27 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1
28 Chelating Agents Phase 3,Phase 2
29 Complement System Proteins Phase 3
30 Analgesics, Non-Narcotic Phase 3
31 PENTA Phase 3,Phase 2
32 Pentetic Acid Phase 3,Phase 2
33 Antacids Phase 2, Phase 3,Phase 1
34 Peripheral Nervous System Agents Phase 3
35 Anticoagulants Phase 3
36 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
37 Antidotes Phase 3,Phase 2
38 Protective Agents Phase 3,Phase 2
39 Iron Chelating Agents Phase 3,Phase 2
40 Anti-Ulcer Agents Phase 2, Phase 3,Phase 1
41 Antipyretics Phase 3,Phase 2
42 Vitamin B12 Nutraceutical Phase 3,Phase 2
43
Cobalamin Nutraceutical Phase 3,Phase 2 13408-78-1 6438156
44
Aluminum sulfate Approved Phase 2 10043-01-3
45 Hops Approved, Nutraceutical Phase 1
46
Salmon Calcitonin Approved, Investigational 47931-85-1 16129616
47 Calcitonin Gene-Related Peptide
48 calcitonin
49 Natriuretic Agents
50 Natriuretic Peptide, Brain

Interventional clinical trials:

(show top 50) (show all 243)

# Name Status NCT ID Phase Drugs
1 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
2 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
3 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Completed NCT00310635 Phase 4
4 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
5 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed NCT00850603 Phase 4
6 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
7 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
8 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
9 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
10 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
11 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Completed NCT02446691 Phase 4
12 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
13 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed NCT01766206 Phase 4
14 Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine Completed NCT00254995 Phase 4
15 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
16 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
17 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
18 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
19 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
20 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
21 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
22 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
23 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
24 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
25 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
26 Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
27 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
28 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
29 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
30 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
31 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
32 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
33 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
34 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
35 A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Enrolling by invitation NCT02868970 Phase 4
36 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
37 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
38 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
39 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Completed NCT01641042 Phase 3
40 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed NCT01682876 Phase 3
41 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers Completed NCT01340898 Phase 3
42 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers Completed NCT00626327 Phase 3
43 Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children Completed NCT00616421 Phase 3
44 Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Completed NCT01890759 Phase 3
45 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India Completed NCT01086969 Phase 3
46 Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose Completed NCT01543087 Phase 3 bivalent rLP2086
47 Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Completed NCT01359449 Phase 3
48 Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children Completed NCT00311415 Phase 3
49 Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age Completed NCT00310674 Phase 3
50 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed NCT01139021 Phase 3

Search NIH Clinical Center for Meningococcal Infection

Genetic Tests for Meningococcal Infection

Anatomical Context for Meningococcal Infection

MalaCards organs/tissues related to Meningococcal Infection:

38
Testes, Brain, Spinal Cord, Spleen, B Cells, Bone, Skin

Publications for Meningococcal Infection

Articles related to Meningococcal Infection:

(show top 50) (show all 247)
# Title Authors Year
1
Self Mutilating Behaviour in Severe Meningococcal Infection; An Interesting Association. ( 27437275 )
2016
2
Meningitis with Digital Gangrene in Meningococcal Infection: An Atypical Presentation. ( 28208911 )
2016
3
Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations. ( 27449147 )
2016
4
Correction: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 27379429 )
2016
5
A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 26872255 )
2016
6
50 Years Ago in TheJournal ofPediatrics: Factors in the Prognosis of Meningococcal Infection: Review of 63 Cases with Emphasis on Recognition and Management of the Severely Ill Patient. ( 26922764 )
2016
7
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection. ( 25553243 )
2015
8
The costs associated with the public health management of a cluster of meningococcal infection in England. ( 25173479 )
2014
9
Public health risk communication by text message in response to a cluster of invasive meningococcal infection in a primary school. ( 24894450 )
2014
10
Severe meningococcal infection: a review of epidemiology, diagnosis, and management. ( 23830646 )
2013
11
Pachymeningitis after meningococcal infection. ( 23642701 )
2013
12
Patterns of meningococcal infection in Sudan with emergence of Neisseria meningitidis serogroup W135. ( 24313147 )
2013
13
Invasive meningococcal infection: analysis of 110 cases from a tertiary care centre in North East India. ( 22821284 )
2013
14
Genetic susceptibility to meningococcal infection. ( 23409824 )
2013
15
Management of a rifampicin-resistant meningococcal infection in a teenager. ( 23408002 )
2013
16
Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England. ( 23467531 )
2013
17
Altered neutrophil counts at diagnosis of invasive meningococcal infection in children. ( 23736141 )
2013
18
Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. ( 22844479 )
2012
19
Diagnosis of meningococcal infection by QPCR: detection and quantification of DNA / Neisseria meningitidis. ( 23272547 )
2012
20
The burden of hospitalizations for meningococcal infection in Spain (1997-2008). ( 21664402 )
2011
21
A teenager with meningococcal infection. ( 21999443 )
2011
22
Real-time impedance analysis of host cell response to meningococcal infection. ( 21078346 )
2011
23
Can near real-time monitoring of emergency department diagnoses facilitate early response to sporadic meningococcal infection?--prospective and retrospective evaluations. ( 20979656 )
2010
24
Disseminated intravascular coagulation, meningococcal infection, and ischemic changes affecting the lower extremities: a case study. ( 20619693 )
2010
25
The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection. ( 20670394 )
2010
26
C7 deficiency and meningococcal infection susceptibility in two spanish families. ( 20591074 )
2010
27
Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. ( 19931914 )
2010
28
Hospital admissions for meningococcal infection in Spain (1997-2005). ( 19042024 )
2009
29
Review of meningococcal infection in children at a United Kingdom hospital. ( 19388559 )
2009
30
Risk of transmitting meningococcal infection by transient contact on aircraft and other transport. ( 19296869 )
2009
31
Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. ( 19477561 )
2009
32
Gram staining: an unexplored diagnostic tool for diagnosis of meningococcal infection in the developing world. ( 19176273 )
2009
33
MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. ( 20072946 )
2009
34
Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease. ( 18927406 )
2008
35
Myocardial infarction after meningococcal infection: a potential inflammatory link or a challenging puzzle? ( 17854929 )
2008
36
Susceptibility to meningococcal infection--nature versus nurture? ( 18779704 )
2008
37
Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection. ( 18679149 )
2008
38
Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. ( 18021301 )
2008
39
Mechanisms of defense formation against meningococcal infection in mice immunized with synthetic peptides. ( 18239810 )
2007
40
Transgenic mice expressing human transferrin as a model for meningococcal infection. ( 17893132 )
2007
41
Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children. ( 16249930 )
2006
42
Prospects for vaccine prevention of meningococcal infection. ( 16418528 )
2006
43
Clinical spectrum of meningococcal infection in infants younger than six months of age. ( 16642734 )
2006
44
Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. ( 16527897 )
2006
45
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. ( 17030578 )
2006
46
Risk factors for death from meningococcal infection in Recife, Brazil. ( 16000346 )
2005
47
Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock. ( 15193387 )
2004
48
Recurrent pericarditis after meningococcal infection. ( 15247622 )
2004
49
Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection. ( 14747454 )
2004
50
Pericarditis after meningococcal infection: case report of a child with two distinct episodes. ( 15014314 )
2004

Variations for Meningococcal Infection

Expression for Meningococcal Infection

Search GEO for disease gene expression data for Meningococcal Infection.

Pathways for Meningococcal Infection

GO Terms for Meningococcal Infection

Cellular components related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 AGT C7 CPB2 G6PD GSR SOD1

Biological processes related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.69 G6PD GSR SOD1
2 response to cold GO:0009409 9.63 ADRB1 ADRB2
3 activation of adenylate cyclase activity GO:0007190 9.62 ADRB1 ADRB2
4 brown fat cell differentiation GO:0050873 9.62 ADRB1 ADRB2
5 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AGT AGTR1
6 positive regulation of cytokine production GO:0001819 9.61 AGT SOD1
7 regulation of vasoconstriction GO:0019229 9.6 AGT AGTR1
8 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.59 ADRB1 ADRB2
9 positive regulation of cellular protein metabolic process GO:0032270 9.58 AGT AGTR1
10 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.58 AGT AGTR1
11 glutathione metabolic process GO:0006749 9.58 G6PD GSR SOD1
12 regulation of blood vessel diameter GO:0097746 9.57 ADRB2 AGTR1
13 positive regulation of superoxide anion generation GO:0032930 9.56 AGT SOD1
14 low-density lipoprotein particle remodeling GO:0034374 9.55 AGT AGTR1
15 cellular sodium ion homeostasis GO:0006883 9.54 AGT C7
16 negative regulation of multicellular organism growth GO:0040015 9.52 ADRB1 ADRB2
17 diet induced thermogenesis GO:0002024 9.49 ADRB1 ADRB2
18 positive regulation of cholesterol esterification GO:0010873 9.48 AGT AGTR1
19 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.46 AGT AGTR1
20 positive regulation of NAD(P)H oxidase activity GO:0033864 9.43 AGT AGTR1
21 renin-angiotensin regulation of aldosterone production GO:0002018 9.37 AGT AGTR1
22 heat generation GO:0031649 9.32 ADRB1 ADRB2
23 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
24 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.16 AGT AGTR1
25 positive regulation of extracellular matrix constituent secretion GO:0003331 8.96 AGT CPB2
26 regulation of renal sodium excretion GO:0035813 8.62 AGT AGTR1

Molecular functions related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 ADD1 ADRB1 AGTR1 TTR
2 NADP binding GO:0050661 9.32 G6PD GSR
3 adrenergic receptor activity GO:0004935 9.16 ADRB1 ADRB2
4 epinephrine binding GO:0051379 8.96 ADRB1 ADRB2
5 norepinephrine binding GO:0051380 8.62 ADRB1 ADRB2

Sources for Meningococcal Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....